Long-term safety study for gene-modified Treg therapy recipients
Part of Bones, joints & muscles, Immune system & allergy, Infections, Skin clinical trials.
This study follows people who previously received a gene-modified Treg (regulatory T cell) therapy from Sonoma Biotherapeutics. It checks for long-term safety and does not involve any new treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received at least one dose of a Sonoma Biotherapeutics gene-modified Treg therapy in an earlier study.
- You understand the purpose and risks of this study and are willing to sign a consent form.
- You agree to follow all study procedures during the follow-up period.
- Your doctor must agree that joining this study is in your best interest.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at certain immune cells (called MAIT cells) in the skin of people with hidradenitis suppurativa, a painful skin condition. It will compare samples from people before they start a new biologic treatment, and may help doctors understand how these treatments work.
This trial tests if stem cells can improve pain and swelling in the knee for people with rheumatoid arthritis that hasn't responded well to standard treatments. It's for those who still have significant knee symptoms despite taking medications.
This study enrolls people with hidradenitis suppurativa (HS) to better understand the condition over time and store optional health information and samples. Being in the registry may help researchers learn about patterns in HS and support future research.
This study is a long-term safety check for people who have already received a gene modified T cell treatment in a previous study sponsored by 2seventy bio or Regeneron Pharmaceuticals. The goal is to monitor your health for years after that treatment to see how well it works and if any side effects appear over time.
This study offers long-term treatment with an investigational biologic, sonelokimab, for people with moderate to severe hidradenitis suppurativa who finished an earlier sonelokimab study. The goal is to see if sonelokimab remains safe and effective over time.
This study tests a new investigational drug, called HRS-8797, in healthy people to see how safe it is and how the body processes it. It's an early-phase trial, so you may not directly benefit, but your participation can help find new treatments for future patients.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.